SEC Form SC 13G/A filed by Agenus Inc. (Amendment)
$AGEN
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/4/2025 | $25.00 | Neutral → Buy | H.C. Wainwright |
| 7/19/2024 | $35.00 → $8.00 | Outperform → Neutral | Robert W. Baird |
| 7/18/2024 | Outperform → Mkt Perform | William Blair | |
| 7/18/2024 | $9.00 | Buy → Neutral | H.C. Wainwright |
| 6/6/2023 | $8.00 | Outperform | Robert W. Baird |
| 6/6/2023 | $60.00 → $80.00 | Outperform | Robert W. Baird |
| 2/28/2023 | $8.00 | Buy | H.C. Wainwright |
| 9/28/2022 | $5.00 | Outperform | SMBC Nikko |
Agenus Inc. ("Agenus") (Nasdaq: AGEN), a leader in immuno-oncology, today announced that the Company will host a virtual Stakeholder Briefing on August 27, 2025 at 4:00 p.m. ET. The event will feature presentations from senior management and industry thought leaders, offering insights into transformative developments that could shape the future of cancer treatment. The agenda includes a strategic and financial overview, achievements tied to the Zydus partnership closing, patient needs fueling interest in colorectal cancer (CRC) studies, recent data from the botensilimab (BOT) and balstilimab (BAL) program, and an overview of the Phase 3 BATTMAN study in metastatic CRC—plus highlights of upc
Zydus Lifesciences collaboration to close in Q3 with $91M capital infusion to support clinical and regulatory milestones BOT/BAL delivers 42% two-year survival in refractory MSS CRC and consistent activity across multiple solid cancers, to be presented at an oral session at ESMO Regulatory alignment secured for Phase 3 trial initiation, expected to commence in Q4 2025 August 27th virtual stakeholder meeting set for a detailed discussion on progress Agenus Inc. ("Agenus" or the "Company") (NASDAQ:AGEN), an immuno-oncology company focused on innovation, today reports financial results for the second quarter of 2025 and highlighted major clinical, regulatory, and operational miles
Agenus Inc. ("Agenus") (Nasdaq: AGEN), a leader in immuno-oncology, today announced that the Company will release its second quarter 2025 financial results before the market opens on Monday, August 11, 2025. Agenus will then host a stakeholder briefing in late August to spotlight key strategic plans, data milestones and provide a comprehensive update on the global botensilimab (BOT) and balstilimab (BAL) development program. About Agenus Agenus is a leading immuno-oncology company targeting cancer with a comprehensive pipeline of immunological agents. The company was founded in 1994 with a mission to expand patient populations benefiting from cancer immunotherapy through combination app
H.C. Wainwright upgraded Agenus from Neutral to Buy and set a new price target of $25.00
Robert W. Baird downgraded Agenus from Outperform to Neutral and set a new price target of $8.00 from $35.00 previously
William Blair downgraded Agenus from Outperform to Mkt Perform
4 - AGENUS INC (0001098972) (Issuer)
4 - AGENUS INC (0001098972) (Issuer)
4 - AGENUS INC (0001098972) (Issuer)
4 - AGENUS INC (0001098972) (Issuer)
4 - AGENUS INC (0001098972) (Issuer)
S-8 - AGENUS INC (0001098972) (Filer)
10-Q - AGENUS INC (0001098972) (Filer)
8-K - AGENUS INC (0001098972) (Filer)
Advertising Veteran Tapped to Elevate Awareness of Agenus and Its Innovative Pipeline Agenus Inc. (NASDAQ:AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced the appointment of Tom Harrison to its Board of Directors. Mr. Harrison brings a wealth of experience and a proven track record in healthcare advertising, branding, and strategic advising. Tom Harrison's Background Highlights: Chairman Emeritus of Diversified Agency Services (DAS), Omnicom Group Inc.: Harrison led the world's largest group of marketing services companies, overseeing an unparalleled range of services including public relations, crisis management, bran
Strategic leadership to drive next phase of growth for the company Agenus Inc. ("Agenus") (NASDAQ:AGEN), a leader in developing novel immunological agents to treat various cancers, is pleased to announce the appointment of Dr. Jennifer Buell to its Board of Directors, on June 11, 2024, effective immediately. Dr. Buell will maintain her active and ongoing role as the President and CEO of MiNK Therapeutics, in addition to her responsibilities as Chairman of the Executive Council at Agenus. Her continued leadership at MiNK ensures a seamless integration of strategic insights across both organizations, enhancing our collaborative efforts to innovate and deliver breakthrough cancer therapies.
Robin Taylor, MBA, Ph.D., Appointed Chief Commercial Officer Homa Yeganegi Appointed Chief Product Strategy and Global Medical Affairs Officer Stephanie Fagan Appointed Chief Communications Officer Immuno-oncology leader, Agenus Inc. ("Agenus") (NASDAQ:AGEN), today announced the appointment of Robin Taylor, Ph.D., Homa Yeganegi and Stephanie Fagan to its executive team. The newly appointed leaders bring a wealth of industry experience to drive the company's next phase of growth in the development and planned commercialization of botensilimab and a deep pipeline of immuno-oncology programs, which offer potential breakthroughs in cancer therapeutics. Chief Commercial Officer, Robin Ta
Agenus Inc. ("Agenus") (Nasdaq: AGEN), a leader in immuno-oncology, today announced that the Company will host a virtual Stakeholder Briefing on August 27, 2025 at 4:00 p.m. ET. The event will feature presentations from senior management and industry thought leaders, offering insights into transformative developments that could shape the future of cancer treatment. The agenda includes a strategic and financial overview, achievements tied to the Zydus partnership closing, patient needs fueling interest in colorectal cancer (CRC) studies, recent data from the botensilimab (BOT) and balstilimab (BAL) program, and an overview of the Phase 3 BATTMAN study in metastatic CRC—plus highlights of upc
Zydus Lifesciences collaboration to close in Q3 with $91M capital infusion to support clinical and regulatory milestones BOT/BAL delivers 42% two-year survival in refractory MSS CRC and consistent activity across multiple solid cancers, to be presented at an oral session at ESMO Regulatory alignment secured for Phase 3 trial initiation, expected to commence in Q4 2025 August 27th virtual stakeholder meeting set for a detailed discussion on progress Agenus Inc. ("Agenus" or the "Company") (NASDAQ:AGEN), an immuno-oncology company focused on innovation, today reports financial results for the second quarter of 2025 and highlighted major clinical, regulatory, and operational miles
$75M upfront payment to Agenus for the transfer of manufacturing assets $50M of contingent payments to Agenus Exclusive license for BOT/BAL in India and Sri Lanka $16M equity investment at $7.50 per share Agenus Inc. (NASDAQ:AGEN), a leader in immuno-oncology innovation, today announced it has signed definitive partnership agreements with Zydus Lifesciences Ltd. (NSE: ZYDUSLIFE), including its subsidiaries/affiliates, hereafter referred to as "Zydus," designed to accelerate clinical development, scale global manufacturing, and expand patient access to botensilimab and balstilimab (BOT/BAL). The strategic collaboration includes an exchange of Agenus' state-of-the-art biologics
SC 13G/A - AGENUS INC (0001098972) (Subject)
SC 13G/A - AGENUS INC (0001098972) (Subject)
SC 13G/A - AGENUS INC (0001098972) (Subject)